FrancophonIA/ELRC3.0 huggingface dataset:
English: However, based on the pharmacokinetic characteristics of levetiracetam, the pharmacokinetics in adults after intravenous administration and the pharmacokinetics in children after oral administration, the exposure (AUC) of levetiracetam is expected to be similar in paediatric patients aged 4 to 12 years after intravenous and oral administration.
Slovenian: Vendar je na osnovi farmakokinetičnih značilnosti levetiracetama, farmakokinetike pri odraslih po intravenskem dajanju in farmakokinetike pri otrocih po peroralnem dajanju, pričakovati pri otrocih, od 4 do 12 let, podobno razpoložljivost (AUC) levetiracetama po intravenskem in peroralnem dajanju.
English: In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Slovenian: Pri odraslih je bila učinkovitost levetiracetama dokazana v 3 dvojno slepih, s placebom nadzorovanih študijah s 1.000 mg, 2.000 mg ali 3.000 mg/dan, razdeljenih na dva odmerka, ter s trajanjem zdravljenja do 18 tednov.
English: How to store Levetiracetam SUN Contents of the pack and other information
Slovenian: Shranjevanje Levetiracetama SUN Vsebina pakiranja in dodatne informacije
English: Levetiracetam SUN concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section 6.6).
Slovenian: Koncentrat zdravila Levetiracetam SUN je samo za intravensko uporabo, priporočeni odmerek mora biti razredčen v vsaj 100 ml kompatibilnega topila in uporabljen intravensko kot 15-minutna intravenska infuzija (glejte poglavje 6.6).
English: Kubickiego 11 02-954 Warszawa Polska tel. +48 22 642 07 75
Slovenian: 02-954 Warszawa Polska tel. +48 22 642 07 75
English: Since there was limited exposure for levetiracetam intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of levetiracetam intravenous will rely on levetiracetam oral use.
Slovenian: Zaradi majhne uporabe zdravila levetiracetama za intravensko uporabo in bioekvivalence med peroralno in intravensko obliko se informacije o varnosti za zdravilo levetiracetama za intravensko uporabo navezujejo na zdravilo levetiracetama za peroralno uporabo.
English: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam.
Slovenian: Ugotovili so, da probenecid (500 mg štirikrat na dan), ki preprečuje ledvično tubularno sekrecijo, zavre ledvični očistek primarnega presnovka, ne pa levetiracetama.
English: The risk of anorexia is higher when levetiracetam is coadministered with topiramate.
Slovenian: Tveganje za pojav anoreksije je večje pri sočasni uporabi levetiracetama in topiramata.
English: It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population.
Slovenian: Ugotovili so, da se levetiracetam pri populaciji v skladu s protokolom ne razlikuje (ni manjvreden) od placeba glede spremembe od začetnih vrednosti rezultatov testiranja spomina in pozornosti (Leiter-R Attention and Memory, Memory Screen Composite).
English: Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Slovenian: Levetiracetam in sorodni analogi kažejo vrstni red afinitete za vezavo na sinaptični vezikularni protein 2A, ki korelira z jakostjo protiepileptične zaščite pri mišjem audiogenem modelu epilepsije.
English: The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents and children using the following formula (Schwartz formula):
Slovenian: CLcr v ml/min/1,73 m2 je pri mlajših mladostnikih, otrocih in dojenčkih, mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) z uporabo naslednje formule (po Schwartz-evi formuli):
English: The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Slovenian: Zdravilna učinkovina levetiracetama je pirolidonski derivat (S-enantiomer α-etil-2-okso1- pirolidinacetamida), ki kemično ni podoben drugim protiepileptičnim učinkovinam.
English: Dose in children 50 kg or greater is the same as in adults.
Slovenian: Pri otrocih, ki s telesno maso 50 kg ali več, je odmerjanje enako kot pri odraslih.
English: The patients were randomized to carbamazepine CR 400 - 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Slovenian: Bolniki so randomizirano prejemali 400-1200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1.000-3.000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov odvisno od odziva.
English: For doctors and nurses, more detailed direction for the proper use of Levetiracetam SUN is provided in section 6.
Slovenian: Za zdravnike in medicinske sestre so podrobna navodila za uporabo zdravila Levetiracetam SUN navedena v poglavju 6.
English: This medicinal product contains 2.5 mmol (or 57 mg) sodium per maximum single dose (0.8 mmol (or 19 mg) per vial).
Slovenian: To zdravilo vsebuje 2,5 mmol (ali 57 mg) natrija v največjem enkratnem odmerku (0,8 mmola (ali 19 mg) na vialo).
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 500 mg/5 ml
Slovenian: VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 500 mg/5 ml
English: Creatinine clearance (ml/min/1.73 m2)
Slovenian: Očistek kreatinina (ml/min/1,73m2)
English: Infusion Time
Slovenian: Čas infuzije Pogostost uporabe
English: There is no experience with administration of intravenous levetiracetam for longer period than 4 days.
Slovenian: Trajanje zdravljenja Ni izkušenj z intravensko uporabo levetiracetama za obdobje daljše od 4 dni.
English: In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile.
Slovenian: Pogosteje kot v drugih starostnih skupinah ali v skupnem varnostnem profilu so pri otrocih in mladostnikih, starih od 4 do 16 let, poročali o bruhanju (zelo pogosto, 11,2 %), agitaciji (pogosto, 3,4 %), nihanjih razpoloženja (pogosto, 2,1 %), čustveni labilnosti (pogosto, 1,7 %), agresiji (pogosto, 8,2 %), nenormalnem vedenju (pogosto, 5,6 %) in letargiji (pogosto, 3,9 %).
English: As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.
Slovenian: Tako kot pri odraslih, tudi pri pediatričnih bolnikih, ki so prejemali do 60 mg/kg/dan levetiracetama, ni jasnih dokazov o klinično značilnem medsebojnem delovanju z zdravili.
English: A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day.
Slovenian: Peri- in postnatalno študijo razvoja so izvedli pri podganah z odmerki levetiracetama od 70, 350 in 1.800 mg/kg/dan.
English: Levetiracetam SUN is used - on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
Slovenian: Zdravilo Levetiracetam SUN se uporablja: - samostojno za zdravljenje pri odraslih in mladostnikih, od 16. leta starosti, z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
English: The intravenous administration of doses up to 4000 mg diluted in 100 ml of 0.9% sodium chloride infused over 15 minutes and doses up to 2500 mg diluted in 100 ml of 0.9% sodium chloride infused over 5 minutes was evaluated.
Slovenian: Ovrednotena je bila intravenska uporaba odmerkov do 4.000 mg, razredčenih v 100 ml 0,9 % natrijevega klorida, infundiranih 15 minut in odmerkov do 2.500 mg, razredčenih v 100 ml 0,9 % natrijevega klorida, infundiranih 5 minut.
English: One vial of Levetiracetam SUN concentrate contains 500 mg levetiracetam (5 ml concentrate of 100 mg/ml).
Slovenian: Ena viala koncentrata zdravila Levetiracetam SUN vsebuje 500 mg levetiracetama (5 ml koncentrata po 100 mg/ml).
English: Diluents: - Sodium chloride 9 mg/ml (0.9%) solution for injection - Lactated Ringer's solution for injection - Dextrose 50 mg/ml (5%) solution for injection
Slovenian: Raztopine: - natrijev klorid 9 mg/ml (0,9 %) raztopina za injiciranje - Ringerjeva raztopina z laktatom za injiciranje - dekstroza 50 mg/ml (5 %) raztopina za injiciranje
English: A single dose of 1500 mg levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1500 mg levetiracetam oral intake, given as three 500 mg tablets.
Slovenian: Enkratni odmerek 1.500 mg levetiracetama, razredčen v 100 ml kompatibilnega topila in 15 minut intravensko infundiran, je bioekvivalenten 1.500 mg peroralnega levetiracetama, to so 3 tablete po 500 mg.
English: Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day.
Slovenian: Dve študiji embrio-fetalnega razvoja pri podganah so izvedli z odmerki 400, 1.200 in 3.600 mg/kg/dan.
English: Adjustment of the dose is recommended in elderly patients with compromised renal function (see "Renal impairment" below).
Slovenian: Pri starejših bolnikih z okvarjenim delovanjem ledvic je priporočljiva prilagoditev odmerka (glejte spodaj »Bolniki z ledvično okvaro«).
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Slovenian: Druga zdravila in zdravilo Levetiracetam SUN Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
English: PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate).
Slovenian: FARMACEVTSKA OBLIKA Koncentrat za raztopino za infundiranje (sterilni koncentrat) Bistra, brezbarvna tekočina.
English: Uncommon: may affect up to 1 in 100 people - decreased number of blood platelets, decreased number of white blood cells - weight decrease, weight increase - suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger,
Slovenian: Občasni: pojavijo se lahko pri največ 1 od 100 bolnikov - zmanjšano število krvnih ploščic, zmanjšano število belih krvnih celic - zmanjšanje telesne mase, povečanje telesne mase - poskus samomora in razmišljanje o samomoru, duševne motnje, nenormalno vedenje,
English: (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration) - diplopia (double vision), vision blurred - elevated/abnormal values in a liver function test - hair loss, eczema, pruritus - muscle weakness, myalgia (muscle pain) - injury
Slovenian: (motena usklajenost mišičnih gibov), parestezija (mravljinčenje), motnje pozornosti (izguba koncentracije) - diplopija (dvojni vid), zamegljen vid - povišane/nenormalne vrednosti testov jetrnih funkcij - izguba las, ekcem, pruritus - šibkost mišic, mialgija (bolečina v mišicah) - poškodba
English: The maximum dose is 1500 mg twice daily.
Slovenian: Največji odmerek je 1.500 mg dvakrat na dan.
English: (2) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
Slovenian: (2) Po dializi je priporočljiv dodatni odmerek od 5 to 10 mg/kg (0,05 do 0,10 ml/kg).
English: Levetiracetam SUN concentrate for solution for infusion can be used when administration of oral levetiracetam is temporarily impossible.
Slovenian: Zdravilo Levetiracetam SUN koncentrat za raztopino za infundiranje se lahko uporablja, kadar uporaba peroralnega protiepileptičnega zdravila Levetiracetam začasno ni mogoča.
English: - weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction - swelling of the face, lips, tongue and throat (Quincke's oedema) - flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) - symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function - a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme) - a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome) - a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis) - signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements.
Slovenian: - šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske (anafilaktične) reakcije - otekanje obraza, ustnic, jezika in žrela (Quinckejev edem) - gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS] - simptome kot so nizek volumen urina, utrujenost, slabost, bruhanje, zmedenost in otekanje nog, gležnjev ali stopal saj so lahko to znaki nenadnega zmanjšanja delovanja ledvic - kožni izpuščaj, ki lahko tvori mehurčke in po videzu spominja na majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem) - široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom) - hujšo obliko, ki povzroči luščenje kože na več kot 30 % telesne površine (toksična epidermalna nekroliza) - znake resnih mentalnih sprememb ali če kdo okoli vas opazi znake zmedenosti, somnolence (zaspanost), amnezije (izguba spomina), oslabljen spomin (pozabljivost), neobičajno vedenje ali druge nevrološke znake vključno z nehotenim ali nenadzorovanim gibanjem.
English: Add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg
Slovenian: Dopolnilno zdravljenje za otroke (od 4 do 11 let) in mladostnike (od 12 do 17 let), s telesno maso manjšo od 50 kg
English: Only limited evidence is available on the neurodevelopment of children exposed to levetiracetam monotherapy in utero.
Slovenian: O nevrološkem razvoju otrok, ki so bili in utero izpostavljeni zdravilu z levetiracetamom, uporabljenim samostojno, so na voljo samo omejeni dokazi.
English: Levetiracetam SUN concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-25°C.
Slovenian: Koncentrat zdravila Levetiracetam SUN je fizikalno kompatibilen in kemijsko stabilen vsaj 24 ur pri mešanju z naslednjimi raztopinami ter shranjen v PVC vrečah pri kontrolirani sobni temperaturi 15 °C do 25 °C.
English: Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes.
Slovenian: Učinkovitost levetiracetama je bila dokazana v dvojno slepi, s placebom nadzorovani 16-tedenski študiji pri bolnikih, od 12 leta starosti, z idiopatsko generalizirano epilepsijo z miokloničnimi napadi pri različnih sindromih.
English: Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Slovenian: Štiri študije embrio-fetalnega razvoja pri kuncih so izvedli z odmerki 200, 600, 800, 1.200 in 1.800 mg/kg/dan.
English: Levetiracetam SUN concentrate for solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-25°C.
Slovenian: Zdravilo Levetiracetam SUN koncentrat za raztopino za infundiranje je fizikalno kompatibilen in kemijsko stabilen vsaj 24 ur pri mešanju z naslednjimi raztopinami ter shranjen v PVC vrečah pri kontrolirani sobni temperaturi 15 °C do 25 °C.
English: If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Slovenian: Praviloma se zdravila ne sme shranjevati več kot 24 ur pri temperaturi 2 °C do 8 °C, razen v primeru redčenja v kontroliranih in validiranih aseptičnih pogojih.
English: 72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week.
Slovenian: Pri 72,2 % bolnikov, ki so se zdravili z levetiracetamom, in 45, 2 % bolnikov, ki so prejemali placebo, je bilo 50 ali več odstotno zmanjšanje pogostnosti PGTC napadov na teden.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 mg of levetiracetam.
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml vsebuje 100 mg levetiracetama.
English: Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.
Slovenian: Odmerjanje pri otrocih (od 4 do 11 let) in mladostnikih (od 12 do 17 let), lažjih od 50 kg Običajni odmerek: med 20 mg na kg telesne mase in 60 mg na kg telesne mase vsak dan.
English: Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more General dose: between 1,000 mg and 3,000 mg each day.
Slovenian: Odmerjanje pri odraslih in mladostnikih (od 12 do 17 let), s telesno maso 50 kg ali več Običajni odmerek: med 1.000 mg in 3.000 mg na dan.
English: One maximum single dose of Levetiracetam SUN concentrate contains 2.5 mmol (or 57 mg) of sodium (0.8 mmol (or 19 mg) of sodium per vial).
Slovenian: Največji enkratni odmerek koncentrata zdravila Levetiracetam SUN vsebuje 2,5 mmol (ali 57 mg) natrija (0,8 mmola (ali 19 mg) natrija na vialo).
English: Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function
Slovenian: Prilagoditev odmerjanja pri otrocih in mladostnikih s telesno maso, manjšo kot 50 kg, z okvarjenim delovanjem ledvic:
English: The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.
Slovenian: Kumulativno se v prvih 48 urah s z urinom izloči 66 % odmerka levetiracetama in 24 % odmerka njegovega primarnega presnovka.
English: The safety and efficacy of Levetiracetam SUN concentrate for solution for infusion in infants and children less than 4 years have not been established.
Slovenian: Dopolnilno zdravljenje za dojenčke in otroke, mlajše od 4 let Varnost in učinkovitost zdravila Levetiracetam SUN, koncentrata za raztopino za infundiranje, pri dojenčkih in pri otrocih, mlajših od 4 let nista bili dokazani.
English: Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase.
Slovenian: Levetiracetam ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.Pri nekaterih bolnikih se lahko zaradi različne individualne občutljivosti predvsem na začetku zdravljenja ali po povečanju odmerka pojavi somnolenca ali drugi simptomi povezani s centralnim živčnim sistemom.
English: Levetiracetam SUN is not indicated in children and adolescents below 16 years on its own (monotherapy).
Slovenian: Zdravilo Levetiracetam SUN, pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija)
English: Name and address of the manufacturer responsible for batch release
Slovenian: Ime in naslov (proizvajalcev), (odgovornih) za sproščanje serij
English: Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Slovenian: Dopolnilno zdravljenje primarno generaliziranih tonično-kloničnih napadov pri odraslih in mladostnikih, od 12. leta starosti, z idiopatsko generalizirano epilepsijo.
English: See Table 1 for the recommended preparation and administration of Levetiracetam SUN concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.
Slovenian: Glejte Preglednico 1 za priporočeno pripravo in uporabo koncentrata zdravila Levetiracetam SUN, da se doseže celotni dnevni odmerek 500 mg, 1.000 mg, 2.000 mg ali 3.000 mg razdeljen na dva odmerka.
English: - The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injection.
Slovenian: - Druge sestavine zdravila so: natrijev trihidrat acetat, koncentrirana ocetna kislina, natrijev klorid, voda za injekcije.
English: 44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week.
Slovenian: Pri 44,6 % bolnikov, ki so se zdravili z levetiracetamom, in 19,6 % bolnikov, ki so prejemali placebo, je bilo 50 ali več odstotno zmanjšanje pogostnosti parcialnih napadov na teden.
English: Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Slovenian: Sočasna uporaba levetiracetama z digoksinom, peroralnimi kontraceptivi in z varfarinom ni vplivala na njegovo farmakokinetiko.
English: Peak plasma concentration (Cmax) observed in 17 subjects following a single intravenous dose of 1500 mg infused over 15 minutes was 51 ± 19 μg/mL (arithmetic average ± standard deviation).
Slovenian: Največja plazemska koncentracija (Cmax) 51 ± 19 μg/mL (aritmetična sredina ± standardna deviacija) je bila pri 17 preiskovancih po enkratnem intravenskem odmerku 1500 mg, infundiranem 15 minut.
English: Sodium acetate trihydrate Glacial acetic acid Sodium chloride Water for injection
Slovenian: Natrijev trihidrat acetat Koncentrirana ocetna kislina Natrijev klorid Voda za injekcije
English: Serum Creatinine (mg/dl) ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male Dosing adjustment for children and adolescents patients weighing less than 50 kg with impaired renal function
Slovenian: ks = 0,55 pri otrocih, mlajših od 13 let in pri mladostnicah; ks = 0,7 pri mladostnikih moškega spola
English: What Levetiracetam SUN contains - The active substance is called levetiracetam.
Slovenian: Kaj vsebuje zdravilo Levetiracetam SUN - Zdravilna učinkovina je levetiracetam.
English: 10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily (1) (2)
Slovenian: 10 do 20 mg/kg (0,10 do 0,20 ml/kg) enkrat na dan (1) (2)
English: Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
Slovenian: Pogostnost je bistveno višja pri japonskih bolnikih v primerjavi z ne-japonskimi bolniki - šepanje ali težave pri hoji.